Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Almirall News

    8,345 € -1,30% -0,11 €
    08:07:08 Uhr Frankfurt aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0MU8Y
    ISIN: ES0157097017
    US-Symbol: LBTSF
    Typ: Aktie
    Werbung
    Weiter aufwärts?
    Long Hebel 5,95
    MB80C3

    Almirall News

    09.05.22 - PLX
    Almirall Q1 EBITDA Falls 19.7% to EUR 59.6 million
    (PLX AI) – Almirall Q1 EBITDA EUR 59.6 million, down 19.7% from a year ago. • Q1 sales EUR 219.7 million, up 1.6% • Says EBITDA decline mainly due to one-offs in Q1 • Says Solid ...
    09.05.22 - PR Newswire
    Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance
    Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance PR Newswire
    09.05.22 - PR Newswire
    Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance
    Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance PR Newswire
    11.04.22 - PR Newswire
    Almirall: Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
    Almirall: Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis PR Newswire
    26.03.22 - PR Newswire
    Almirall: Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Pivotal Phase 3 Atopic Dermatitis Studies
    Almirall: Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Pivotal Phase 3 Atopic Dermatitis Studies PR Newswire
    21.02.22 - PLX
    Almirall Reports 2021 Sales of EUR 809.8 Million; Sees 2022 Total EBITDA EUR 190-210 Million
    (PLX AI) – Almirall FY sales EUR 809.8 million. • FY EBITDA EUR 235.6 million • FY core EBITDA EUR 211.3 million • Says key products poised for accelerating sales growth in the ...
    21.02.22 - PR Newswire
    Dr. Jorge Gallardo Ballart announces his intention to retire from his positions of President of the Board of Directors and Board member of Almirall
    Dr. Jorge Gallardo Ballart announces his intention to retire from his positions of President of the Board of Directors and Board member of Almirall PR Newswire
    21.02.22 - PR Newswire
    Dr. Jorge Gallardo Ballart announces his intention to retire from his positions of President of the Board of Directors and Board member of Almirall
    Dr. Jorge Gallardo Ballart announces his intention to retire from his positions of President of the Board of Directors and Board member of Almirall The resignation will be effective as ...
    21.02.22 - PR Newswire
    Almirall's Full-Year 2021 Results : Almirall delivers high end of the 2021 upgraded guidance with solid performance from growth drivers
    Almirall's Full-Year 2021 Results : Almirall delivers high end of the 2021 upgraded guidance with solid performance from growth drivers PR Newswire
    21.02.22 - PR Newswire
    Almirall's Full-Year 2021 Results : Almirall delivers high end of the 2021 upgraded guidance with solid performance from growth drivers
    Almirall's Full-Year 2021 Results : Almirall delivers high end of the 2021 upgraded guidance with solid performance from growth drivers PR Newswire
    18.02.22 - PR Newswire
    Almirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalp
    Almirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalp PR Newswire
    21.12.21 - PR Newswire
    Almirall: Lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study
    Almirall: Lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study ...
    15.11.21 - PR Newswire
    Almirall delivers solid nine months 2021 results and tightens its upgraded guidance
    Almirall delivers solid nine months 2021 results and tightens its upgraded guidance PR Newswire
    15.11.21 - PR Newswire
    Almirall delivers solid nine months 2021 results and tightens its upgraded guidance
    Almirall delivers solid nine months 2021 results and tightens its upgraded guidance PR Newswire
    08.11.21 - PR Newswire
    Almirall U.S. Supports The Skin Cancer Foundation's Mobile Skin Cancer Screening Program
    Almirall U.S. Supports The Skin Cancer Foundation's Mobile Skin Cancer Screening Program PR Newswire
    06.10.21 - PR Newswire
    Almirall S.A.: Experts highlight the need to focus on psoriasis patients' wellbeing in clinical practice
    Almirall S.A.: Experts highlight the need to focus on psoriasis patients' wellbeing in clinical practice PR Newswire
    27.09.21 - PR Newswire
    Almirall Launches Klisyri®▼(Tirbanibulin) for the Treatment of Actinic Keratosis in Europe
    Almirall Launches Klisyri®▼(Tirbanibulin) for the Treatment of Actinic Keratosis in Europe PR Newswire
    16.08.21 - PR Newswire
    Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic deramatitis in two Phase 3 trials
    Lebrikizumab significantly improved skin clearance and itch in people with moderate-​to-severe atopic deramatitis in two Phase 3 trials PR Newswire
    26.07.21 - PR Newswire
    Almirall delivers robust H1 performance and increases full-year guidance
    Almirall delivers robust H1 performance and increases full-year guidance PR Newswire
    26.07.21 - PR Newswire
    Almirall delivers robust H1 performance and increases full-year guidance
    Almirall delivers robust H1 performance and increases full-year guidance - Robust business performance with significant growth in Core EBITDA: Core Net Sales €415.5 MM (+8% ...

    Newssuche

    Videos

    09:15 Uhr +4,64%
    Technical Trading: Sojabohnen Long bis Juli
    Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »